IHH Healthcare Bhd delivered double-digit growth across its key financial metrics in the second quarter of 2026 (2Q26), supported by resilient operating performance across its multinational healthcare portfolio.
Core revenue on a constant-currency basis rose 19% year-on-year (YoY) to RM6.9 billion, while core profit after tax and minority interests (PATMI), excluding exceptional items, increased 30% YoY to RM675 million.
The group attributed the stronger performance to higher inpatient and daycase volumes, coupled with an increase in the proportion of complex cases treated across its network.
At the country level, Malaysia, Türkiye and Europe, and India recorded strong performances during the quarter.
In Malaysia, growth was driven by higher revenue intensity and inpatient admissions, alongside double-digit increases in daycase volumes and revenue.
Türkiye and Europe continued to register broad-based growth, supported by strong demand from both local and foreign patients despite additional bed capacity at Kartal, Kent and Bayindir hospitals.
India, meanwhile, continued to benefit from the integration of Fortis Healthcare and Gleneagles India through their maintenance services agreement, alongside organic growth.
Singapore remained on track for a recovery in the second half of 2026, in line with previous guidance.
Occupancy at IHH’s Singapore operations improved from the lows recorded in the first quarter to 51% in 2Q26, while margins remained strong at 29%.
IHH Singapore continued to focus on increasing patient volumes, including the launch of new packages with leading insurers during the quarter. More price-competitive packages are expected to be introduced in the coming months.
On a reported basis, IHH’s 2Q26 revenue increased 12% YoY to RM7.0 billion, while reported PATMI rose 29% YoY to RM573 million.
The group said the strength of its diversified portfolio helped mitigate global volatility, although the stronger Ringgit had a translation impact on its reported financial results.
For the first half of 2026 (1H26), IHH recorded 17% YoY growth in both core revenue and core PATMI on a constant-currency basis, reaching RM13.4 billion and RM1.2 billion respectively.
The growth was supported by continued operational strength across Malaysia, Türkiye and Europe, and India.
On a reported basis, 1H26 revenue increased 8% YoY to RM13.6 billion, while reported PATMI rose 15% YoY to RM1.1 billion.
IHH also maintained a strong financial position, with cash balances of RM1.3 billion as at June 30, 2026, while net gearing stood at 0.4 times.
The group said its strong cash flow generation, active cost discipline and prudent capital management continued to support the balance sheet despite the challenging global operating environment.
Overall, the 1H26 performance underscores the resilience of IHH’s diversified multinational healthcare portfolio, with continued growth in its core markets and an anticipated recovery in Singapore providing support for the group’s outlook for the remainder of 2026.
